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Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127S114thrombocytopenia was given the remainder of his stem cells
on day +31 due with subsequent normalization of his CBC.
Conclusions: Mobilization with G-CSF and Plerixafor was
well tolerated in AL patients with multiple organs involved.
Limited leukaphereses were needed to achieve or exceed the
target CD34+ cell dose. In the era of more effective initial
therapies, an era in which many AL patients are living longer
with moderate to severe organ damage and receiving mul-
tiple lines of therapy including SCT, this approach allows not
only the collection of sufﬁcient CD34+ cells for optimal im-
mediate stem cell dosing, but also the cryopreservation of
aliquots for future transplants should they become necessary
and for novel cell-based therapies should they become
available.145
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In spite of intensive multimodal therapy including HSCT, it is
difﬁcult to assess remission in NB. We have previously
demonstrated thatWT1is a surrogate marker of proliferation
in leukemia. To assess the status of NB cell proliferation post
HSCT, WT1 gene expression was evaluated. 42 random bone
marrow (BM) samples (from 34 patients) were obtained, at
diagnosis (n¼24) and post HSCT (n¼18; 13 in remission and
5 in clinical relapse). Quantitative RT-PCR was used for the
evaluation of the level of gene expression as positive (> 1 x
100 ng/ml), weakly positive (9.9 x 10-1 to 6.5 x 10-1 ng/ml) and
negative (< 6.5 x 10-1 ng/ml). Results were extrapolated from
a ten fold serial dilution standard curve using a NB cell line
(NGP). The levels of WT1 gene expression in NGP were
arbitrarily deﬁned as 1.0. The integrity of RNAwas conﬁrmed
by ampliﬁcation of the housekeeping gene GAPDH. At diag-
nosis 83% (18/24 positive, 2/24 weakly positive) (95.9 + 74.2
(0.890- 1500) ng/ml) patients expressed theWT1 gene, where
17% (4/24) (0.199 + 0.0946 (0.007- 0.440) ng/ml) were nega-
tive. Post HSCT in remission 92% (12/13) were negative
(0.0822 + 0.0192 (0.0026-0.200) ng/ml) in comparison to the
time of clinical relapse where 60% (3/5) (1.57 + 0.418 (1.10 e
2.40) ng/ml) were positive for WT1 gene expression. A com-
parison t-test was performed between the initial gene
expression at diagnosis to remission and only positive WT1
gene expression at diagnosis to clinical relapse. Signiﬁcant
difference (p<.0002) was found when comparing WT1
transcription at diagnosis to remission, whereas insigniﬁ-
cance (p<.5) was found when comparing positive WT1
expression at diagnosis to clinical relapse. This signiﬁes that
the WT1 gene is indicative of cellular proliferation further
illustrating the status of BM involvement in NB patients post
HSCT.146
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AuHCT is commonly an inpatient procedure. Due to im-
provements in supportive care, many centers now perform
AuHCT on an outpatient basis. We compared the outcome of
95 outpatients (OP) and 135 inpatients (IP) that underwent a
ﬁrst AuHCT from July 2009 to December 2012 formyeloma or
lymphoma usingmelphalan or BEAM conditioning at a single
center. Selection for OP AutoHCT was based on expected
compliance, proximity to the cancer center for daily visits,
24-hour caregiver support, and favorable performance status
and co-morbidity proﬁle. Both groups received the same
chemotherapy or supportive care, except that the OP group
received more aggressive prophylactic antibiotic support
during neutropenia and received pegﬁlgrastim on day +1.
The IP group received daily ﬁlgrastim starting on day +5.
The OP and IP cohorts were similar in terms of primary
disease (myeloma vs. lymphoma), median age, gender, and
chemo-sensitivity pre-transplant. Karnofsky Performance
Status (KPS) was less favorable in the IP cohort with KPS80
in 36% vs. 6% in the OP cohort (p<.001). There was a trend
toward less favorable Hematopoietic Cell Transplant Co
morbidity Index (HCT-CI) in the IP cohort as well with 53% of
the patients having HCT-CI >/¼3 vs. 40% in the OP cohort
(p¼.060). With regard to transplant characteristics, OP and IP
received a similar CD34 cell dose (4.4 vs. 4.6 x 106/kg,
respectively, p¼.581). Hematopoietic recovery occurred
earlier in the OP cohort, with median time to neutrophil
recovery of 10 vs. 11 days (p<.001) and median time to
platelet recovery of 19 vs. 20 days (p¼.053). For OP AuHCT,
overall 51%were never admitted; for patients transplanted in
2011-2012 this ﬁgure was 61%. For the OP that were
admitted, median length of stay was 9 days. In comparison,
the IP AuHCT patients had a median length of stay of 19 days.
Grade 3-4 non-hematologic toxicities occurred in 29% of both
the OP and IP cohorts. There were no signiﬁcant differences
in speciﬁc adverse events between the two cohorts,
including febrile neutropenia, bacteremia, Clostridium difﬁ-
cile infections, central venous line complications, and
engraftment syndrome. Non-relapse mortality at one year
was 0% in the OP cohort and 1.5% in the IP cohort (p¼.327).
Two year PFS was 62% for OP vs. 54% for IP (p¼.155). One and
two year OS was 97% and 83% for OP vs. 91% and 80% for IP,
respectively (p¼.271).
We conclude that, with careful patient selection and minor
modiﬁcation to the management of neutropenia, OP AuHCT
can result in excellent outcomes for myeloma and lymphoma
patients. OPAuHCT also offers beneﬁt for patients in terms of
enhanced comfort, fewer days in the hospital, and decreased
exposure to sick contacts. Lastly, OP AuHCT is beneﬁcial to
transplant centers due to decreased hospital resource utili-
zation.147
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